Multiple myeloma: practice patterns across Europe.
Raab MS et al. Br J Haematol. 2016 Jun 13. doi: 10.1111/bjh.14193. [Epub ahead of print].

The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V et al. Mayo Clin Proc. 2016 Jun;91(6):707-12. doi: 10.1016/j.mayocp.2016.04.028.

Pomalidomide in the management of relapsed multiple myeloma.
Touzeau C et al. Future Oncol. 2016 Jun 10. [Epub ahead of print].

Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Musto P et al. Expert Rev Hematol. 2016 Jun 16:1-9. [Epub ahead of print].

Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
Maybury B et al. Biol Blood Marrow Transplant. 2016 Jun 8. pii: S1083-8791(16)30135-5. doi:
10.1016/j.bbmt.2016.06.004. [Epub ahead of print].

Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
Anreddy N et al. J Cell Biochem. 2016 Jun 4. doi: 10.1002/jcb.25617. [Epub ahead of print].

Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
LeBlanc R et al. J Popul Ther Clin Pharmacol. 2016;23(1):e103-13. Epub 2016 Jun 7.

Management of high-risk Myeloma: an evidence-based review of treatment strategies.
Lehners N et al. Expert Rev Hematol. 2016 Jun 23. [Epub ahead of print].

Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.
Schinasi LH et al. Br J Haematol. 2016 Jun 22. doi: 10.1111/bjh.14199. [Epub ahead of print].

Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study.
Seminog OO et al. J R Soc Med. 2016 Jun 20. pii: 0141076816651037. [Epub ahead of print].

3-Formylchromone inhibits proliferation and induces apoptosis of multiple myeloma cells by abrogating STAT3 signaling through the induction of PIAS3.
Ko JH et al. Immunopharmacol Immunotoxicol. 2016 Jun 21:1-29. [Epub ahead of print].

Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
Grosicki S et al. Expert Rev Hematol. 2016 Jun 20. [Epub ahead of print].

Recurrent Light Chain Proximal Tubulopathy in a Kidney Allograft.
Angioi A et al. Am J Kidney Dis. 2016 Jun 17. pii: S0272-6386(16)30171-8. doi: 10.1053/j.ajkd.2016.04.021. [Epub ahead of print].

Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L et al. Br J Haematol. 2016 Jun 17. doi: 10.1111/bjh.14145. [Epub ahead of print].

Frequent MUGA testing in a myeloma patient: A case-based ethics discussion.
Bhatti S et al. J Nucl Cardiol. 2016 Jun 6. [Epub ahead of print].

The ethics of radiation exposure in cancer-treated patients : Editorial for: Frequent MUGA testing in a myelomapatient: a case-based ethics discussion.
Chen-Scarabelli C et al. J Nucl Cardiol. 2016 Jun 16. [Epub ahead of print].

Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myelomaamong US community oncology practices.
Jagannath S et al. Expert Rev Hematol. 2016 Jun 16:1-11. [Epub ahead of print].

Non Coding RNAs: a new avenue for the self-tailoring of blood cancer treatment.
Misso G et al. Curr Drug Targets. 2016 Jun 5. [Epub ahead of print].

Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.
Liu JD et al. Sci Rep. 2016 Jun 7;6:27361. doi: 10.1038/srep27361.

The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.
Robinson D Jr et al. Br J Haematol. 2016 Jun 5. doi: 10.1111/bjh.14058. [Epub ahead of print].

Pesticide exposures and the risk of multiple myeloma in men: An analysis of the North American Pooled Project (NAPP).
Presutti R et al. Int J Cancer. 2016 Jun 4. doi: 10.1002/ijc.30218. [Epub ahead of print].

Time-Dependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults.
Dankner R et al. Am J Epidemiol. 2016 Jun 15;183(12):1098-106. doi: 10.1093/aje/kwv290. Epub 2016 Jun 2.

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myelomafrom a US perspective.
Jakubowiak AJ et al. J Med Econ. 2016 Jun 16:1-14. [Epub ahead of print].

ASCO Plenary Sessions: impact, legacy, future.
Vandross A et al. Semin Oncol. 2016 Jun;43(3):321-6. doi: 10.1053/j.seminoncol.2016.03.001.